REG - C4X Discovery - Last day of dealings and update on cancellation

C4X Discovery HoldingsAnnouncement

25/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240425:nRSY9372La&default-theme=true

RNS Number : 9372L  C4X Discovery Holdings PLC  25 April 2024

 

 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Last day of dealings and update on Cancellation

 

25 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today provides a further update with regards to the
proposed cancellation of admission of the Company's ordinary shares to trading
on AIM (the "Cancellation"), as originally announced on 27 March 2024 and as
approved by shareholders at the general meeting held on 15 April 2024.

 

Shareholders are reminded that the last day of trading in the Ordinary Shares
on AIM is today, 25 April 2024, and Cancellation will become effective at 7:00
a.m. on 26 April 2024. Following Cancellation, the Company will re-register as
a private company under the name C4X Discovery Holdings Limited.

 

As previously announced, the Company has engaged Asset Match
(www.assetmatch.com), a firm Authorised and Regulated by the Financial Conduct
Authority (FRN 579310), to operate an electronic off-market dealing facility
for the ordinary shares. This facility will allow existing shareholders of the
Company and new investors to trade ordinary shares by matching buyers and
sellers through periodic auctions. Further details can be found on the
Company's website www.c4xdiscovery.com (http://www.c4xdiscovery.com) . The
Asset Match facility will be effective from 8 a.m. on 26 April 2024.
Investors may wish to register on www.assetmatch.com
(https://www.assetmatch.com) and add C4X Discovery to their 'Watchlist' to
continue to receive auction/price information and updates.

 

Shareholders will continue to be able to hold their shares in uncertificated
form (i.e. in CREST) and should check with their existing stockbroker whether
they are willing or able to trade in unquoted shares. Shareholders wishing to
trade shares through Asset Match must do so through a stockbroker. A
comprehensive list of stockbrokers who have signed up to access the Asset
Match platform is available on request.

 

Following Cancellation, shareholders are encouraged to sign up to the
Company's email news alerts via the C4XD website to remain up to date with the
Company's developments as we continue to advance our portfolio and target
opportunities as a private company.

 

Further details regarding the cancellation and re-registration are set out in
the circular sent to shareholders dated 27 March 2024. A copy of the circular
is available on the Company's website www.c4xdiscovery.com
(http://www.c4xdiscovery.com) .

 

Following Cancellation, Panmure Gordon (UK) Limited will cease to act as
nominated adviser and corporate broker to the Company.

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner                          +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining
scientific expertise with cutting-edge technologies to efficiently deliver
world‑leading medicines. We have a highly valuable and differentiated
approach to Drug Discovery through our enhanced molecular design and patient
stratification capabilities, generating small molecule drug candidates across
multiple disease indications focused on immuno-inflammation. We are advancing
our internal portfolio which ranges from early-stage target opportunities to
late-stage Drug Discovery programmes and we have two commercially partnered
programmes with Sanofi and AstraZeneca, and one clinical stage candidate which
has been acquired by Indivior.

 

For more information visit us at www.c4xdiscovery.com
(http://www.c4xdiscovery.com) or follow us on twitter @C4XDiscovery.

 

About Asset Match

Asset Match operates an open auction system where volumes of bids and offers
at different prices are displayed on-screen together with the closing date of
the auction. At the end of each auction period, Asset Match passes this
information through a non-discretionary algorithm that determines a
"market-derived" single clearing price ("Share Price") based on supply and
demand and allocates transactions accordingly. Bids and offers may be made,
amended and withdrawn at any time before the closing date of each auction.

 

For more information, see www.assetmatch.com (https://www.assetmatch.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCIIMPTMTATBLI